Cargando…

Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation

Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsebaey, Mohamed A., Elbedewy, Tamer A., Elashry, Heba, Elrefaey, Waleed, Elshweikh, Samah A., Elhadidy, Ahmed A., Shalaby, Neveen A., Elsokkary, Assem Mohamed, Elashtokhy, Hossam Eldin A., Abo-Amer, Yousry Esam-Eldin, Abo-Elfetoh, Ashraf Rafat, Hassanien, Sharaf Elsayed Ali, Fouad, Amina, Abdellatif, Raghda Samir, Ismail, Amro Abdelaziz Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704936/
https://www.ncbi.nlm.nih.gov/pubmed/36451458
http://dx.doi.org/10.1097/MD.0000000000031962
_version_ 1784840169206054912
author Elsebaey, Mohamed A.
Elbedewy, Tamer A.
Elashry, Heba
Elrefaey, Waleed
Elshweikh, Samah A.
Elhadidy, Ahmed A.
Shalaby, Neveen A.
Elsokkary, Assem Mohamed
Elashtokhy, Hossam Eldin A.
Abo-Amer, Yousry Esam-Eldin
Abo-Elfetoh, Ashraf Rafat
Hassanien, Sharaf Elsayed Ali
Fouad, Amina
Abdellatif, Raghda Samir
Ismail, Amro Abdelaziz Mohammed
author_facet Elsebaey, Mohamed A.
Elbedewy, Tamer A.
Elashry, Heba
Elrefaey, Waleed
Elshweikh, Samah A.
Elhadidy, Ahmed A.
Shalaby, Neveen A.
Elsokkary, Assem Mohamed
Elashtokhy, Hossam Eldin A.
Abo-Amer, Yousry Esam-Eldin
Abo-Elfetoh, Ashraf Rafat
Hassanien, Sharaf Elsayed Ali
Fouad, Amina
Abdellatif, Raghda Samir
Ismail, Amro Abdelaziz Mohammed
author_sort Elsebaey, Mohamed A.
collection PubMed
description Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains controversial. The aim of the study was to determine the incidence of HBVr and HBV-related hepatitis in resolved HBV patients who received immunosuppressive therapy with or without antiviral prophylaxis. This retrospective study included 64 patients with resolved HBV infection who received different regimens of immunosuppressive medications, with moderate risk of HBVr, for variable underlying diseases. Patients who had chronic HBV infection or other viral infections were excluded. Patients who received B-cell depleting therapies were ruled out. They were divided into 2 groups: group 1 included 31 patients who received immunosuppressive therapy without antiviral prophylaxis, and group 2 included 33 patients who received antiviral prophylaxis (entecavir) within 2 weeks of commencing the immunosuppressive therapy. HBVr, HBV-related hepatitis, and HBV-unrelated hepatitis were assessed along a 1-year duration. The overall HBVr incidence was 1.56% (1/64). This patient who had HBVr was seen in group 1. There were no significant differences between the 2 groups regarding the incidence of HBVr, HBV-related hepatitis, HBV-unrelated hepatitis, and immunosuppressive therapy interruption along a 1-year duration. Based on this retrospective study, close monitoring was equal to antiviral prophylaxis regarding the outcome of resolved HBV patients who received moderate risk immunosuppressive therapy. HBV treatment should commence once HBVr is confirmed.
format Online
Article
Text
id pubmed-9704936
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97049362022-11-29 Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation Elsebaey, Mohamed A. Elbedewy, Tamer A. Elashry, Heba Elrefaey, Waleed Elshweikh, Samah A. Elhadidy, Ahmed A. Shalaby, Neveen A. Elsokkary, Assem Mohamed Elashtokhy, Hossam Eldin A. Abo-Amer, Yousry Esam-Eldin Abo-Elfetoh, Ashraf Rafat Hassanien, Sharaf Elsayed Ali Fouad, Amina Abdellatif, Raghda Samir Ismail, Amro Abdelaziz Mohammed Medicine (Baltimore) 4500 Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies. HBV monitoring versus antiviral prophylaxis against HBVr in those patients remains controversial. The aim of the study was to determine the incidence of HBVr and HBV-related hepatitis in resolved HBV patients who received immunosuppressive therapy with or without antiviral prophylaxis. This retrospective study included 64 patients with resolved HBV infection who received different regimens of immunosuppressive medications, with moderate risk of HBVr, for variable underlying diseases. Patients who had chronic HBV infection or other viral infections were excluded. Patients who received B-cell depleting therapies were ruled out. They were divided into 2 groups: group 1 included 31 patients who received immunosuppressive therapy without antiviral prophylaxis, and group 2 included 33 patients who received antiviral prophylaxis (entecavir) within 2 weeks of commencing the immunosuppressive therapy. HBVr, HBV-related hepatitis, and HBV-unrelated hepatitis were assessed along a 1-year duration. The overall HBVr incidence was 1.56% (1/64). This patient who had HBVr was seen in group 1. There were no significant differences between the 2 groups regarding the incidence of HBVr, HBV-related hepatitis, HBV-unrelated hepatitis, and immunosuppressive therapy interruption along a 1-year duration. Based on this retrospective study, close monitoring was equal to antiviral prophylaxis regarding the outcome of resolved HBV patients who received moderate risk immunosuppressive therapy. HBV treatment should commence once HBVr is confirmed. Lippincott Williams & Wilkins 2022-11-25 /pmc/articles/PMC9704936/ /pubmed/36451458 http://dx.doi.org/10.1097/MD.0000000000031962 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4500
Elsebaey, Mohamed A.
Elbedewy, Tamer A.
Elashry, Heba
Elrefaey, Waleed
Elshweikh, Samah A.
Elhadidy, Ahmed A.
Shalaby, Neveen A.
Elsokkary, Assem Mohamed
Elashtokhy, Hossam Eldin A.
Abo-Amer, Yousry Esam-Eldin
Abo-Elfetoh, Ashraf Rafat
Hassanien, Sharaf Elsayed Ali
Fouad, Amina
Abdellatif, Raghda Samir
Ismail, Amro Abdelaziz Mohammed
Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
title Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
title_full Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
title_fullStr Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
title_full_unstemmed Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
title_short Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
title_sort resolved hepatitis b infection in patients receiving immunosuppressive therapy: monitor versus prophylaxis against viral reactivation
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704936/
https://www.ncbi.nlm.nih.gov/pubmed/36451458
http://dx.doi.org/10.1097/MD.0000000000031962
work_keys_str_mv AT elsebaeymohameda resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT elbedewytamera resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT elashryheba resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT elrefaeywaleed resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT elshweikhsamaha resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT elhadidyahmeda resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT shalabyneveena resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT elsokkaryassemmohamed resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT elashtokhyhossameldina resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT aboameryousryesameldin resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT aboelfetohashrafrafat resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT hassaniensharafelsayedali resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT fouadamina resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT abdellatifraghdasamir resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation
AT ismailamroabdelazizmohammed resolvedhepatitisbinfectioninpatientsreceivingimmunosuppressivetherapymonitorversusprophylaxisagainstviralreactivation